Medline (MDLN) Q3 2026 earnings review
Medline raises its sales plan, while inflation squeezes gross profit
Medline, the largest US provider of medical-surgical supplies, grew underlying operating profit again while GAAP gross margin kept shrinking. Third-quarter sales rose 10% to $7.9 billion, above what the company's own flat sequential plan pointed to. Chief executive Jim Boyle raised the full-year sales outlook for a third time, and operating profit excluding tariff refunds rose 2% by our math after two quarters of double-digit drops.
| Sales from businesses owned a year ago | +10.5% $7.86B total net sales (+10.4%) |
|---|---|
| Operating profit (Adjusted EBITDA) ex tariff refunds | $879M +2.3% from a year ago by our math |
| Nine-month free cash flow | $1.80B +50% from a year ago |
| Full-year underlying sales outlook | Raised 0.75 pts middle of the range: 10.25% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because underlying operating profit stopped falling and cash generation lowered debt to 2.5 times profit, funding a $750 million loan prepayment and a $1 billion buyback plan. One caution: GAAP gross margin still fell nearly 2 percentage points on a $122 million inventory inflation charge, and the distribution segment's profit margin slipped to 4.4%.
The question now is whether Medline can pass rising product costs on to hospitals and convert new distribution clients to its high-margin in-house brands. If it succeeds, earnings will grow alongside sales in 2027; if inflation and low-margin distribution dominate, profit margins stay compressed. Fourth-quarter segment margins and the 2027 outlook next quarter will settle it.
🐂 Bull Case
Operating Profit Stopped Falling Without Tariff Refunds
Medline tracks Adjusted EBITDA, its main measure of operating profit before interest, taxes, depreciation and one-off charges. In the first half of 2026, that profit fell more than 10% from a year earlier once temporary tariff refunds are stripped out. In the third quarter, the medical-supplies group recognized another $81 million of net tariff refunds following a February Supreme Court ruling.
Excluding that $81 million refund, underlying Adjusted EBITDA rose 2.3% from a year ago to $879 million by our math, and climbed 7.6% from the second quarter. That rebound ended two straight quarters of double-digit drops, even though the third quarter had one fewer selling day. The company kept its full-year profit outlook unchanged rather than cutting it again.
What to watch: fourth-quarter Adjusted EBITDA excluding tariff refunds. To reach the middle of the full-year plan, fourth-quarter profit must rise about 9% from a year ago to $878 million by our math, which will show whether the margin recovery is durable.
New Hospital Contracts Keep Driving Top-Line Raises
Chief executive Jim Boyle said "Medline delivered another strong quarter, with double-digit net sales growth, reflecting continued momentum across our business." Sales from businesses owned a year ago (organic sales) rose 10.5% to $7.86 billion, beating the company's prior plan for sales to stay near the second quarter's $7.69 billion. Even excluding an $11 million customer repayment adjustment, underlying sales grew 10.4% by our math.
Hospitals signing up for Supply Chain Solutions, Medline's distribution service for medical products made by other manufacturers, drove the beat as 2025 contracts took effect. Segment sales rose 13.9% to $4.22 billion, prompting the company to raise its full-year sales outlook for a third straight quarter.
What to watch: total new customer signings — the yearly value of new contracts — in the fourth-quarter report. Boyle noted "continued progress toward our annual total new customer signings" goal of $1 billion, and the full-year number will show how much growth remains for 2027.
Cash Generation Funded Debt Paydown and a First Buyback
Free cash flow — operating cash after capital spending — reached $1.80 billion over the first nine months, up 49.6% from a year ago. In the third quarter alone, the healthcare distributor generated $884 million of free cash flow by our math, even after spending $348 million over nine months on "investments in automation across the distribution network, construction of new distribution centers and expansion of kitting manufacturing capacity".
Strong cash flow pushed net debt down by $938 million in the quarter to $9.14 billion, lowering net debt to 2.5 times annual Adjusted EBITDA from 2.9 times in June. In October, Medline prepaid $750 million of its 2033 term loan and approved a $1 billion share buyback programme for "investing in the business, continued debt reduction and opportunistic return of capital to shareholders".
What to watch: actual share repurchases in the fourth quarter. Buying back stock while private-equity sponsors still hold exchangeable partnership units will test whether the company uses cash to offset dilution or just holds the authorization in reserve.
🐻 Bear Case
Cost Inflation Still Squeezes Gross Margin
While Adjusted EBITDA grew, total net income slipped 1.2% from a year ago to $318 million, which Medline said was "primarily driven by increased inventory costs associated with inflation, higher operating expenses, and customer mix." Gross margin fell 1.9 percentage points to 24.5% because the cost of making and buying products rose to 75.5% of sales.
- Cost of goods sold: up 1.9 percentage points of sales as reported, or 2.9 percentage points excluding $70 million of tariff refunds in cost of goods by our math
- Last-in, first-out (LIFO) inventory inflation charge: $122 million in the quarter, up from $2 million a year ago and $32 million in the first half
- Adjusted EBITDA: excludes the $122 million LIFO inventory charge, shielding the headline profit figure from rising product costs
This matters because the company adds back non-cash LIFO inventory charges when calculating Adjusted EBITDA. That accounting treatment hides how much raw-material and fuel inflation is still hitting the income statement while management holds back on raising prices for hospitals.
What to watch: the fourth-quarter LIFO inventory adjustment and gross margin. Another triple-digit inventory charge would mean input inflation is not easing and will keep squeezing GAAP profit into 2027.
Distribution Growth Still Dilutes the Profit Mix
Medline earns most of its profit in the Medline Brand segment, which sells its own medical products and carried a 25.9% Adjusted EBITDA margin this quarter (23.8% excluding tariff refunds by our math). Its other segment, Supply Chain Solutions, distributes third-party products and earned a 4.4% margin.
Because new hospital contracts start in distribution before converting to in-house products, Supply Chain Solutions grew 13.9% while Medline Brand grew 6.6%. That lowered Medline Brand's share of total sales to 46.3% from 47.9% a year ago by our math. Meanwhile, the distribution margin dropped 1.1 percentage points from 5.5% a year ago and fell below the 4.9% to 5.0% full-year level management targeted last quarter.
What to watch: Supply Chain Solutions margin and Medline Brand's sales share in the fourth quarter. If the distribution margin stays near 4.4% and the brand share keeps falling, first-year customer rebates and warehouse labor are costing more than planned.
FDA Remediation and Bed Recalls Add New Charges
Medline has been working through quality problems across its manufacturing network, including three unresolved US Food and Drug Administration (FDA) warning letters disclosed in prior filings. Boyle cited progress with global quality initiatives in the release, and the footnotes quantify the direct bills for the first time.
During the third quarter, the Northfield-based group booked $13 million of remediation costs in response to FDA observations and warning letters, plus another $13 million for recall and discontinuation costs on Medline Brand hospital beds. Both charges were excluded from Adjusted EBITDA as non-core items, alongside $11 million of transformation project costs.
What to watch: FDA remediation and recall charges in the fourth-quarter footnotes, plus any update on when recalled products return to market. Stopping these charges and restoring lost product sales is necessary to lift Medline Brand growth back toward double digits.
Risks this quarter didn't answer
Three standing concerns from earlier in the year received no new figures in the third-quarter press release.
- New customer signings pace: management gave no third-quarter dollar figure after reporting $650 million in the first half against a $2.4 billion total in 2025; the fourth-quarter report will give the full-year number.
- Tax Receivable Agreement (TRA) liability: obligations to pay pre-IPO owners for tax benefits stayed at $4.40 billion, and future sponsor share exchanges could still expand this cash drain.
- 2027 tariff exposure: the release did not update how Section 301 tariffs will affect cost of goods sold once current inventory turns over in early 2027.
💲 Other KPIs
Net interest expense fell 44.6% from $213 million a year ago and edged down from $119 million in the second quarter. Debt paydowns from the late-2025 initial public offering and a May 2026 refinancing drove the $95 million quarterly savings, and October's $750 million loan prepayment will lower interest costs further.
Overhead and distribution payroll rose 12.8% from a year ago, taking 16.0% of net sales compared with 15.7% last year. That 0.3 percentage point increase was smaller than in the first half, when the medical supplier hired warehouse staff ahead of new hospital contracts and overhead reached 16.9% of sales in the second quarter.
In the second quarter, a fire at the Tracy, California distribution center caused a $336 million pre-tax loss in other operating expenses. In the third quarter, the US distributor recorded a net $20 million credit from insurance proceeds, reducing the nine-month net fire loss to $316 million.
🔮 Guidance
Raised. The company lifted its full-year underlying sales growth target by 0.75 percentage points at the middle of the range to 10.25%. By our math, that leaves about 9.0% underlying growth for the fourth quarter, down from 10.5% in the third quarter as the company laps last year's big contract launches. It is the third raise this year: +0.5 points, +0.5 points, and +0.75 points.
Unchanged. The plan still has full-year operating profit excluding tariff refunds falling about 3.4% at the middle of the range from $3.47 billion in 2025. By our math, with $2.47 billion earned over the first nine months excluding $324 million of refunds, fourth-quarter profit must reach $828–928 million, or up 9.1% from a year ago at the middle of the range.
❓ Key Questions
Why did the distribution margin drop to 4.4%?
Supply Chain Solutions Adjusted EBITDA margin fell 1.1 percentage points from a year ago to 4.4%, below last quarter's 4.9% to 5.0% full-year expectation. Did customer rebates, warehouse labor, or fuel costs drive the miss?
What drove the $122 million LIFO inventory charge?
Non-cash LIFO inventory inflation charges jumped from $32 million in the first half to $122 million in the third quarter alone. Which product categories saw cost increases, and will Medline raise prices to cover them?
How much new contract value was signed in Q3?
Management cited progress toward its $1 billion annual new signings goal after booking over $650 million in the first half, but gave no dollar figure. Where do year-to-date signings stand against last year's $2.4 billion?
When will the FDA warning letters and bed recalls end?
Medline booked $26 million in the quarter for FDA warning letter remediation and Medline Brand bed recalls. What is the remaining cost to resolve the three warning letters, and when do recalled products return?